Chronic myeloid leukemia: state of the art in 2012.

Item

http://www.wikidata.org/entity/Q38028374

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Chronic myeloid leukemia: state of the art in 2012.

@en

type

Item

label

Chronic myeloid leukemia: state of the art in 2012.

@en

prefLabel

Chronic myeloid leukemia: state of the art in 2012.

@en

P1476

Chronic myeloid leukemia: state of the art in 2012.

@en

P2093

Carmen Fava

http://www.w3.org/2001/XMLSchema#string

Giovanna Rege-Cambrin

http://www.w3.org/2001/XMLSchema#string

Giuseppe Saglio

http://www.w3.org/2001/XMLSchema#string

P2860

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

Overriding imatinib resistance with a novel ABL kinase inhibitor

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia.

Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia.

Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase.

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).

P2888

s11912-012-0253-9

P304

379-386

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11912-012-0253-9

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1011662138

http://www.w3.org/2001/XMLSchema#string

P698

22821153

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

chronic myeloid leukemia